for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Molecular Medicine SpA

MLMD.MI

Latest Trade

0.34EUR

Change

-0.01(-1.44%)

Volume

636,573

Today's Range

0.34

 - 

0.35

52 Week Range

0.25

 - 

0.47

As of on the Italian SE (Mercato Continuo Italia) ∙ Minimum 15 minute delay

Pricing

Previous Close
0.35
Open
0.35
Volume
636,573
3M AVG Volume
21.17
Today's High
0.35
Today's Low
0.34
52 Week High
0.47
52 Week Low
0.25
Shares Out (MIL)
463.45
Market Cap (MIL)
160.59
Forward P/E
--
Dividend (Yield %)
--

Next Event

Molecular Medicine SpA Annual Shareholders Meeting

Latest Developments

More

Molmed Decides To Withdraw Conditional Marketing Authorization Of Zalmoxis

Molecular Medicine H1 Net Loss Narrows To EUR 1.9 Mln

Molmed Suspends Enrollment Of New Patients In Phase III Study TK008 With Zalmoxis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Molecular Medicine SpA

Molecular Medicine SpA (MolMed) is an Italy-based company engaged in the medical biotechnology sector. The Company is active in the research, development and clinical validation of therapies for the treatment of cancer. The Company’s activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue. MolMed’s pipeline comprises two main investigational anticancer therapies: TK, which is a cell-based therapy for the treatment of leukemia, and NGR-hTNF, which is a biological drug targeting tumor blood vessels for the treatment of solid tumors. MolMed develops, conducts and validates custom studies, creating testing procedures and addressing the test specifications required for cell-based therapies. It is also active in the production of cell-based medicinal products used in clinical trials and drug development of cell-based therapies.

Industry

Biotechnology & Drugs

Contact Info

Via Olgettina, 58

+39.02.212771

http://www.molmed.com

Executive Leadership

Carlo Incerti

Chairman of the Board

Riccardo Palmisano

Chief Executive Officer

Salvatore Calabrese

Chief Financial Officer

Claudio Bordignon

Chairman of the Scientific Advisory Board

Cynthia Marina Giuliani

Director of Human Resources & General Services

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
4.94
Price To Book (MRQ)
7.41
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
42.11
LT Debt To Equity (MRQ)
36.59
Return on Investment (TTM)
-9.56
Return on Equity (TTM)
-6.66

Latest News

Latest News

BRIEF-MolMed Q1 Net Loss Narrows To EUR 0.7 Mln

* REPORTED ON MONDAY Q1 OPERATING REVENUE EUR 7.9 MLN VS EUR 5.8 MLN YEAR AGO

BRIEF-MolMed FY Net Loss Shrinks To EUR 4.1 Mln

* REPORTED ON MONDAY FY TOTAL OPERATING REVENUE OF EUR 29.9 MILLION VERSUS EUR 24.0 MILLION A YEAR AGO

BRIEF-Molmed SpA Signs Master Service Agreement With Boston Children's Hospital For Supply Of Lentiviral Vectors

* SIGNS 5 YEAR MASTER SERVICE AGREEMENT WITH BOSTON CHILDREN'S HOSPITAL FOR SUPPLY OF LENTIVIRAL VECTORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed FY Net Loss Shrinks To EUR 8.5 Mln

* REPORTED ON FRIDAY FY TOTAL OPERATING REVENUES EUR 24.0 MLN VS EUR 22.8 MLN YEAR AGO

BRIEF-Molmed: Dompé Exercises Option To Start Zalmoxis In Switzerland, Turkey And Australia

* DOMPÉ EXERCISES OPTION TO ENTER MARKETS IN SWITZERLAND, TURKEY AND AUSTRALIA TO SELL ZALMOXIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed: Italian Medicines Agency Sets Price Of Reimbursement For Zalmoxis

* ITALIAN MEDICINES AGENCY SETS GROSS PRICE OF REIMBURSEMENT FOR ZALMOXIS AT EUR 149,000 PER INFUSION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed submits utilization request for third tranche of share capital increase

* SUBMITTED UTILIZATION REQUEST FOR THIRD TRANCHE OF SHARE CAPITAL INCREASE TO BE RESERVED TO SOCIETE GENERALE AS PER SEF AGREEMENT

BRIEF-Molmed completes second tranche of share capital increase reserved to Societe Generale

* SECOND TRANCHE OF SHARE CAPITAL INCREASE RESERVED TO SOCIETE GENERALE PURSUANT TO “SEF - STANDBY EQUITY FACILITY” AGREEMENT COMPLETED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed H1 net loss shrinks to EUR 6.5 million

* REPORTED ON THURSDAY H1 OPERATING REVENUE EUR 9.8 MILLION VERSUS 10.2 MILLION A YEAR AGO

BRIEF-Molmed signs development and production agreement with Cellectis

* SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Molmed signs strategic commercialization and supply agreements with Dompe

* MOLMED AND DOMPE SIGN 15-YEAR LICENSE AND DISTRIBUTION AGREEMENT FOR SUPPLY OF ZALMOXIS IN EUROPE

BRIEF-Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories

* MOLMED AND TTY BIOPHARM ENTER INTO AN EXCLUSIVE AGREEMENT TO COMMERCIALISE ZALMOXIS® IN CERTAIN ASIAN TERRITORIES

BRIEF-MolMed and Megapharm enter into a license and distribution agreement for Zalmoxis in Israel

* Molmed and Megapharm sign licensing and distribution contract for Zalmoxis in Israel

BRIEF-MolMed and Rocket Pharma sign collaboration agreement for treatment of Fanconi Anemia

* MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia

BRIEF-MolMed and TTY sign term sheet to commercialise Zalmoxis in certain Asian territories

* MolMed and TTY Biopharm (TTY)sign a term sheet to commercialise Zalmoxis in certain Asian territories

BRIEF-MolMed exercises power to carry out capital increase of up to 42 mln shares

* Said on Tuesday that the board exercised the power to carry out the capital increase to be reserved to Societe Generale of up to 42,000,000 ordinary shares and within the limit of 10 percent of the existing share capital

BRIEF-MolMed Q3 net loss widens to EUR 5.9 mln

* Reported on Monday Q3 net loss of 5.9 million euros ($6.52 million) versus loss 5.3 million euros a year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up